Physician profile
Martha J Lemons
NPI 1629469184
$10,946.32
in general payments reported to CMS, 2019-2025
43 companies · $2,093 in 2025
The $2,093 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,871 · 2022: $2,466 · 2023: $1,762 · 2024: $1,754 · 2025: $2,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,587.94 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,953.19 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $1,447.00 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,241.81 | 2021-2025 | Relistor |
| Abbvie INC. | $1,124.68 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,066.29 | 2021-2025 | Belbuca, Xtampza |
| Astrazeneca Pharmaceuticals LP | $684.13 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $620.34 | 2021-2023 | Tepezza, Krystexxa |
| Abbott Laboratories | $535.26 | 2021-2025 | Proclaim, Octrode, Eterna |
| Ibsa Pharma INC. | $259.55 | 2021-2022 | |
| Pfizer INC. | $175.13 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $152.00 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $146.09 | 2023-2025 | Horizant, Horizant |
| Biodelivery Sciences International, INC. | $129.10 | 2021 | |
| Tersera Therapeutics LLC | $83.25 | 2022-2025 | Prialt |
| Aurinia Pharma U.S., INC. | $81.89 | 2022-2024 | Lupkynis |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Lemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.